Lakefront Biotherapeutics (LKFT) Retained Earnings (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Retained Earnings for 13 consecutive years, with -$9.8 million the latest figure, recorded in Q1 2026.

• Quarterly Retained Earnings fell 67.11% year-over-year to -$9.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.8 million (down 67.11% YoY) and the FY2025 annual result came in at -$9.8 million, up 93.57% from the prior year.
• Retained Earnings was little changed at -$9.8 million in Q1 2026 per LKFT's latest filing, from -$9.8 million in the prior quarter.
• Over the last five years, Retained Earnings for LKFT reached as high as -$5.5 million in Q1 2023 and fell as low as -$565.2 million in Q4 2022.
• A 5-year average of -$62.2 million and a median of -$9.8 million in 2026 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings jumped 98.81% — and 2024, when it slumped 2180.24%.
• Year by year, Retained Earnings stood at -$565.2 million in 2022, then soared by 98.81% to -$6.7 million in 2023, then sank by 2180.24% to -$152.8 million in 2024, then soared by 93.57% to -$9.8 million in 2025, then increased by 0.1% to -$9.8 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$9.8 million, -$9.8 million, and -$10.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.